Records containing: Rheumatoid Arthritis
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2021-01-07A Randomized, Open-Label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants
-
CLINICAL_TRIALS study record update · 2021-01-07Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease
-
CLINICAL_TRIALS study record update · 2021-01-05Effect of Laser Puncture on Rheumatoid Arthritis Patients
-
CLINICAL_TRIALS study record update · 2020-12-29Impact of the Rheumatoid Factor on Serological Testing Performance for Covid-19 in Rheumatoid Arthritis Patients
-
CLINICAL_TRIALS study record update · 2020-12-28Nerve Block of the Proximal Interphalyngeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2020-12-22A Multi-center, Noninterventional Study With Certolizumab Pegol in Comparison With Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2020-12-21Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe
-
CLINICAL_TRIALS study record update · 2020-12-19A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2020-12-19Real-life Experience of Tofacitinib in Patients With Treatment-Resistant Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2020-12-19A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2020-12-17Post-Market Clinical Follow-Up (PMCF) Study of the CLS Brevius Stem With Kinectiv Technology
-
CLINICAL_TRIALS study record update · 2020-12-11A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients
-
CLINICAL_TRIALS study record update · 2020-12-11Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak
-
CLINICAL_TRIALS study record update · 2020-12-11A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients
-
CLINICAL_TRIALS study record update · 2020-12-04A Randomized, Double-Blind, Parallel-Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Given As a Single Infusion or Dual Infusion Compared With Placebo in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
-
CLINICAL_TRIALS study record update · 2020-12-03A Study to Assess Efficacy and Safety of Wangbi Capsule in Patients With Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2020-12-01Ultrasound as Biomarker for Withdrawal of Biological DMARDs in Rheumatoid Arthritis
-
CLINICAL_TRIALS study record update · 2020-12-01A Phase III Multi-center, Double-blind, Placebo-controlled, Parallel Group 24-Week Study to Assess the Efficacy and Safety of Two Dose Regimens of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate.
-
CLINICAL_TRIALS study record update · 2020-12-01A Phase III Multicentre, Double Blind, Placebo-controlled, Parallel Group 52-week Study to Assess the Efficacy and Safety of 2 Dose Regimens of Lyophilised CDP870 as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms and Preventing Structural Damage in Patients With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate
-
CLINICAL_TRIALS study record update · 2020-11-27RHYTHM (RHeumatoid Arthritis studY of THe Myocardium): How Rheumatoid Arthritis (RA) and Tumor Necrosis Factor (TNF) Inhibitors Affect the Myocardial Structure and Function.
-
CLINICAL_TRIALS study record update · 2020-11-27A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment
-
CLINICAL_TRIALS study record update · 2020-11-24Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT
-
CLINICAL_TRIALS study record update · 2020-11-23Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
-
CLINICAL_TRIALS study record update · 2020-11-20For 12 Weeks, the Multi Center, Randomized, Double Blinded, Placebo Controlled, Parallel, Dose-finding Clinical Study for the Therapeutic Exploration of Safety and Efficacy Assessment of HL237 Tablet in Patients With Rheumatoid Arthritis (Phase IIa)
-
CLINICAL_TRIALS study record update · 2020-11-19Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone